VEGFA and neoplasm: Antiangiogenic agents targeting the dominant angiogenic mediators vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) could normalize pathologic tumor vasculature, modulate the tumor microenvironment, and suppress neovascularization [16, 17].